#United States #Redwood City #Drug Development #Trellis Bioscience #Calpurbatug

Trellis Bioscience Secures $9 Million in Series C Funding

Trellis Bioscience, an emerging player in the biotechnology sector, has recently finalized a $9 million Series C funding round aimed at furthering the clinical development of its investigational monoclonal antibody treatment, Calpurbatug (TRL1068). This financing initiative will facilitate the ongoing Phase 2 trial targeting chronic prosthetic joint infections (PJI), a serious and often difficult-to-treat complication arising from joint replacement surgeries.

Overview of Trellis Bioscience

Founded with the mission to innovate treatments for intractable infectious diseases, Trellis focuses on developing native human monoclonal antibodies that hold promise for treating various conditions. The company has now amassed nearly $35 million in total equity funding, supported not only by continuing investors such as New Science Ventures and Easton Capital but also by new stakeholders including the AMR Action Fund and orthopedic experts from across the nation.

CEO Geoff Dillon of Trellis expressed enthusiasm about the input from AMR, emphasizing its pivotal role in addressing the urgent need for new solutions in the antimicrobial space. This funding will bolster the company’s commitment to redefining how antibiotic-resistant infections—specifically those related to PJI—are handled, utilizing Calpurbatug’s novel mechanism to disrupt bacterial biofilm, the protective barrier that bacteria form to evade treatment.

The Challenge of Prosthetic Joint Infections

Prosthetic joint infections pose significant challenges, affecting approximately 1-2 percent of all joint replacement patients in the United States each year. With over 25,000 cases annually, the financial implications are staggering—estimates suggest that managing these infections could cost upwards of $400,000 per patient due to extensive treatment needs and associated healthcare expenditures. Traditional treatment often involves invasive surgical procedures that significantly impair patients' quality of life and entail high rates of surgical failure and mortality.

The current standard treatment protocol involves costly two-stage revisions, and although a less invasive strategy termed DAIR (debridement, antibiotics, implant retention) exists, it often suffers from lower success rates—especially in chronic cases.

Calpurbatug's Breakthrough Potential

Calpurbatug, having already shown promise in early clinical trials, aims to tackle bacterial resistance at its source. By effectively dismantling the biofilm that hampers antibiotic efficacy, it has the potential to outperform conventional treatment strategies. Jason Adams from The Doctor Group highlighted the encouraging preliminary results of clinical trials, suggesting that this innovative drug could significantly enhance patient outcomes compared to traditional approaches, marking a significant advancement in the field.

Addressing a Growing Healthcare Crisis

Amidst a backdrop of an aging population poised to undergo more joint replacement surgeries, the challenge of managing PJIs continues to escalate. AMR Action Fund’s CEO, Henry Skinner, voiced support for Trellis’s innovative approach, noting that the rising threat of antimicrobial resistance makes developing effective treatments more vital than ever. Improving patient outcomes while also preserving the integrity of existing antibiotics is critical for maintaining modern surgical practices.

Development Status and Regulatory Approvals

Under an FDA-cleared IND application, Trellis has successfully conducted its first human trials for Calpurbatug in PJI patients. The outcomes of these trials have established critical safety parameters and provided initial evidence that supports the drug's biofilm-disrupting capabilities. The ongoing Phase 2 trial, which involves fully enrolled PJI patients undergoing DAIR procedures, is anticipated to yield results by the second quarter of 2027.

Additionally, Calpurbatug has received several FDA designations, including Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP), all of which may expedite its development and confer exclusive market advantages once approval is granted.

Final Thoughts

As Trellis Bioscience stands on the cusp of redefining treatment methodologies for PJI, its innovative approach encapsulated in Calpurbatug not only presents hope for improved patient care but also signifies a meaningful step forward in the ongoing battle against antibiotic-resistant infections. The support from key investors reiterates the belief in the necessity for novel solutions in the ever-evolving landscape of healthcare.